Tonix Pharmaceuticals (NASDAQ:TNXP) Stock Price Down 13.8% – What’s Next?

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) dropped 13.8% during mid-day trading on Tuesday . The stock traded as low as $0.15 and last traded at $0.17. Approximately 73,990,631 shares traded hands during trading, a decline of 35% from the average daily volume of 113,742,805 shares. The stock had previously closed at $0.19.

Analyst Ratings Changes

Separately, StockNews.com initiated coverage on Tonix Pharmaceuticals in a research report on Sunday. They set a “hold” rating for the company.

Tonix Pharmaceuticals Price Performance

The stock has a market capitalization of $28.41 million, a price-to-earnings ratio of 0.00 and a beta of 2.07. The company has a quick ratio of 2.81, a current ratio of 3.33 and a debt-to-equity ratio of 0.07. The business has a 50-day simple moving average of $0.30 and a two-hundred day simple moving average of $0.27.

Tonix Pharmaceuticals (NASDAQ:TNXP) last released its earnings results on Tuesday, November 12th. The company reported ($0.23) earnings per share for the quarter, topping analysts’ consensus estimates of ($2.03) by $1.80. The firm had revenue of $2.82 million during the quarter, compared to the consensus estimate of $2.63 million. Tonix Pharmaceuticals had a negative return on equity of 163.95% and a negative net margin of 1,197.86%. As a group, research analysts predict that Tonix Pharmaceuticals Holding Corp. will post -17.63 earnings per share for the current fiscal year.

Institutional Trading of Tonix Pharmaceuticals

An institutional investor recently bought a new position in Tonix Pharmaceuticals stock. PFG Investments LLC purchased a new position in Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor purchased 218,003 shares of the company’s stock, valued at approximately $72,000. PFG Investments LLC owned about 0.12% of Tonix Pharmaceuticals at the end of the most recent quarter. Institutional investors own 82.26% of the company’s stock.

Tonix Pharmaceuticals Company Profile

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.